Possible future avenues for myositis therapeutics: DM, IMNM and IBM - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Best Practice and Research: Clinical Rheumatology Année : 2022

Possible future avenues for myositis therapeutics: DM, IMNM and IBM

Résumé

Idiopathic inflammatory myopathies (IIMs) represent a heterogeneous group of systemic autoimmune diseases characterized by immune-mediated muscle injury. As insights into pathogenesis of IIM evolve, novel therapeutic strategies have become available to optimize outcomes. Herein, we summarize novel and emerging strategies in the management of dermatomyositis (DM), immunemediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM).

Mots clés

Fichier non déposé

Dates et versions

hal-03832475 , version 1 (27-10-2022)

Identifiants

Citer

Caoilfhionn Connolly, Lotta Plomp, Julie Paik, Yves Allenbach. Possible future avenues for myositis therapeutics: DM, IMNM and IBM. Best Practice and Research: Clinical Rheumatology, 2022, 36 (2), pp.101762. ⟨10.1016/j.berh.2022.101762⟩. ⟨hal-03832475⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More